- Conditions
- Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
- Interventions
- Venglustat GZ/SAR402671
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 178
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsed/Refractory Solid Tumors/Hematological Malignancies
- Interventions
- Belinostat
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Whittier, California • Canton, Ohio
- Conditions
- Chronic Kidney Diseases, Hypertension
- Interventions
- KBP-5074 0.25 mg tablet, KBP-5074 0.5 mg tablet
- Drug
- Lead sponsor
- KBP Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Princeton, New Jersey • Morrisville, North Carolina
- Conditions
- Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment
- Interventions
- BMS-986278
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Renal Impairment
- Interventions
- varespladib methyl
- Drug
- Lead sponsor
- Anthera Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
- Conditions
- Chronic Kidney Diseases, Pruritus
- Interventions
- Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 83
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Surprise, Arizona + 76 more
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
- Interventions
- Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 204
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
- Conditions
- Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
- Interventions
- Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination
- Drug
- Lead sponsor
- Atea Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Tampa, Florida
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- albiglutide
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 5
- States / cities
- Anniston, Alabama • Miami, Florida • Orlando, Florida + 2 more
- Conditions
- Neoplasms
- Interventions
- Regorafenib (Stivarga, BAY73-4506)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more
- Conditions
- Neuromuscular Blockade, Renal Impairment
- Interventions
- Cisatracurium + Neostigmine, Rocuronium + Sugammadex
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Chronic Kidney Disease
- Interventions
- Placebo, AST-120
- Drug
- Lead sponsor
- Tanabe Pharma Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,020 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Alhambra, California + 38 more
- Conditions
- Atherosclerosis
- Interventions
- Darapladib 160 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Minneapolis, Minnesota
- Conditions
- Renal Impairment
- Interventions
- YM178
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Anaheim, California • Miami, Florida
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Glimepiride, Placebo, Linagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 16
- States / cities
- Chula Vista, California • Pembroke Pines, Florida • Decatur, Georgia + 11 more
- Conditions
- Kidney Failure, Acute, Renal Insufficiency, Acute, Kidney Failure, Renal Insufficiency
- Interventions
- Early Renal Involvement
- Other
- Lead sponsor
- Saint Louis VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Acute Kidney Injury, Heart Failure, Contrast Induced Nephropathy, Coronary Angiography, Percutaneous Coronary Intervention
- Interventions
- Remote ischemic preconditioning, Sham remote ischemic conditioning
- Device
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 3
- States / cities
- Pittsburgh, Pennsylvania • Dallas, Texas • Richmond, Virginia
- Conditions
- Renal Impairment
- Interventions
- Mezigdomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 82 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Miami Lakes, Florida • Orlando, Florida
- Conditions
- Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe), Diabetes
- Interventions
- DM199
- Drug
- Lead sponsor
- DiaMedica Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 3
- States / cities
- Hialeah, Florida • Orlando, Florida • Saint Paul, Minnesota
- Conditions
- CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
- Interventions
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
- Drug
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
- Interventions
- sorafenib tosylate, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Kidney Disease, IgA Nephropathy
- Interventions
- Bortezomib (Velcade®)
- Drug
- Lead sponsor
- The Rogosin Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Renal Impairment
- Interventions
- Topirmate and Phentermine
- Drug
- Lead sponsor
- VIVUS LLC
- Industry
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Anaheim, California • Miami, Florida • Orlando, Florida + 1 more
- Conditions
- Acute Kidney Injury
- Interventions
- 0.9% sodium chloride, Physiologically balanced fluid
- Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 974 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee